A novel high-dose therapy regimen with Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) followed by autologous stem cell rescue is safe and highly effective for resistant/relapsed lymphoma patients: a phase I-II study on 44 patients

作者:Visani G; Capria S; Stefani P M; Gaudio F; Malerba L; Galieni P; Cuberli F; Sarina B; Specchia G; Meloni G; Giardini C; Gherlinzoni F; Falcioni S; Loscocco F; Gobbi M; Santoro A; Rocchi M; Ocio E; Caballero M D; Isidori A
来源:37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, 2011-04-03 to 2011-04-06.
  • 出版日期2011-4